Intravitreal and systemic foscarnet in the treatment of AIDS-related CMV retinitis

M. S. Tognon, B. Turrini, G. Masiero, R. Scaggiante, P. Cadrobbi, F. Baldanti, G. Gerna, A. G. Secchi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Cytomegalovirus retinitis is the most frequent ocular opportunistic infection in AIDS patients. Untreated, it is always a progressive and destructive disease of the retina that results in blindness. Specific treatment is therefore mandatory to half the progression of the retinal lesions. The authors report their experience in the treatment of CMV retinitis with foscarnet in 25 AIDS patients; the drug is an analog of pyrophosphate, virostatic against all herpes-class viruses including CMV. Foscarnet was successful in halting the progression of CMV retinitis during induction treatment (180 mg/kg/day) by either a TID (three times a day) or a BID (twice a day) regimen, and in healing retinal lesions during maintenance (90 mg/kg/day) in 14 out of 19 patients. Five patients had a relapse of retinitis during maintenance. In these patients a brief course of intra vitreal foscarnet, in association with the lowest dosage of the drug administered systematically (90 mg/kg/day), was effective in healing the retinal lesions. The main systemic side effects, such as renal impairment and electrolytic disturbances, were observed only during the induction treatment, and only in one case was it necessary to stop the therapy.

Original languageEnglish
Pages (from-to)179-182
Number of pages4
JournalEuropean Journal of Ophthalmology
Volume6
Issue number2
Publication statusPublished - Apr 1996

Fingerprint

Foscarnet
Retinitis
Acquired Immunodeficiency Syndrome
Maintenance
Cytomegalovirus Retinitis
Therapeutics
Eye Infections
Opportunistic Infections
Blindness
Pharmaceutical Preparations
Retina
Viruses
Kidney
Recurrence

Keywords

  • AIDS
  • CMV retinitis
  • Foscarnet
  • Intravitreal therapy

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Tognon, M. S., Turrini, B., Masiero, G., Scaggiante, R., Cadrobbi, P., Baldanti, F., ... Secchi, A. G. (1996). Intravitreal and systemic foscarnet in the treatment of AIDS-related CMV retinitis. European Journal of Ophthalmology, 6(2), 179-182.

Intravitreal and systemic foscarnet in the treatment of AIDS-related CMV retinitis. / Tognon, M. S.; Turrini, B.; Masiero, G.; Scaggiante, R.; Cadrobbi, P.; Baldanti, F.; Gerna, G.; Secchi, A. G.

In: European Journal of Ophthalmology, Vol. 6, No. 2, 04.1996, p. 179-182.

Research output: Contribution to journalArticle

Tognon, MS, Turrini, B, Masiero, G, Scaggiante, R, Cadrobbi, P, Baldanti, F, Gerna, G & Secchi, AG 1996, 'Intravitreal and systemic foscarnet in the treatment of AIDS-related CMV retinitis', European Journal of Ophthalmology, vol. 6, no. 2, pp. 179-182.
Tognon MS, Turrini B, Masiero G, Scaggiante R, Cadrobbi P, Baldanti F et al. Intravitreal and systemic foscarnet in the treatment of AIDS-related CMV retinitis. European Journal of Ophthalmology. 1996 Apr;6(2):179-182.
Tognon, M. S. ; Turrini, B. ; Masiero, G. ; Scaggiante, R. ; Cadrobbi, P. ; Baldanti, F. ; Gerna, G. ; Secchi, A. G. / Intravitreal and systemic foscarnet in the treatment of AIDS-related CMV retinitis. In: European Journal of Ophthalmology. 1996 ; Vol. 6, No. 2. pp. 179-182.
@article{8c8326f5cd7a47de9ee26a5fa907e040,
title = "Intravitreal and systemic foscarnet in the treatment of AIDS-related CMV retinitis",
abstract = "Cytomegalovirus retinitis is the most frequent ocular opportunistic infection in AIDS patients. Untreated, it is always a progressive and destructive disease of the retina that results in blindness. Specific treatment is therefore mandatory to half the progression of the retinal lesions. The authors report their experience in the treatment of CMV retinitis with foscarnet in 25 AIDS patients; the drug is an analog of pyrophosphate, virostatic against all herpes-class viruses including CMV. Foscarnet was successful in halting the progression of CMV retinitis during induction treatment (180 mg/kg/day) by either a TID (three times a day) or a BID (twice a day) regimen, and in healing retinal lesions during maintenance (90 mg/kg/day) in 14 out of 19 patients. Five patients had a relapse of retinitis during maintenance. In these patients a brief course of intra vitreal foscarnet, in association with the lowest dosage of the drug administered systematically (90 mg/kg/day), was effective in healing the retinal lesions. The main systemic side effects, such as renal impairment and electrolytic disturbances, were observed only during the induction treatment, and only in one case was it necessary to stop the therapy.",
keywords = "AIDS, CMV retinitis, Foscarnet, Intravitreal therapy",
author = "Tognon, {M. S.} and B. Turrini and G. Masiero and R. Scaggiante and P. Cadrobbi and F. Baldanti and G. Gerna and Secchi, {A. G.}",
year = "1996",
month = "4",
language = "English",
volume = "6",
pages = "179--182",
journal = "European Journal of Ophthalmology",
issn = "1120-6721",
publisher = "Wichtig Publishing",
number = "2",

}

TY - JOUR

T1 - Intravitreal and systemic foscarnet in the treatment of AIDS-related CMV retinitis

AU - Tognon, M. S.

AU - Turrini, B.

AU - Masiero, G.

AU - Scaggiante, R.

AU - Cadrobbi, P.

AU - Baldanti, F.

AU - Gerna, G.

AU - Secchi, A. G.

PY - 1996/4

Y1 - 1996/4

N2 - Cytomegalovirus retinitis is the most frequent ocular opportunistic infection in AIDS patients. Untreated, it is always a progressive and destructive disease of the retina that results in blindness. Specific treatment is therefore mandatory to half the progression of the retinal lesions. The authors report their experience in the treatment of CMV retinitis with foscarnet in 25 AIDS patients; the drug is an analog of pyrophosphate, virostatic against all herpes-class viruses including CMV. Foscarnet was successful in halting the progression of CMV retinitis during induction treatment (180 mg/kg/day) by either a TID (three times a day) or a BID (twice a day) regimen, and in healing retinal lesions during maintenance (90 mg/kg/day) in 14 out of 19 patients. Five patients had a relapse of retinitis during maintenance. In these patients a brief course of intra vitreal foscarnet, in association with the lowest dosage of the drug administered systematically (90 mg/kg/day), was effective in healing the retinal lesions. The main systemic side effects, such as renal impairment and electrolytic disturbances, were observed only during the induction treatment, and only in one case was it necessary to stop the therapy.

AB - Cytomegalovirus retinitis is the most frequent ocular opportunistic infection in AIDS patients. Untreated, it is always a progressive and destructive disease of the retina that results in blindness. Specific treatment is therefore mandatory to half the progression of the retinal lesions. The authors report their experience in the treatment of CMV retinitis with foscarnet in 25 AIDS patients; the drug is an analog of pyrophosphate, virostatic against all herpes-class viruses including CMV. Foscarnet was successful in halting the progression of CMV retinitis during induction treatment (180 mg/kg/day) by either a TID (three times a day) or a BID (twice a day) regimen, and in healing retinal lesions during maintenance (90 mg/kg/day) in 14 out of 19 patients. Five patients had a relapse of retinitis during maintenance. In these patients a brief course of intra vitreal foscarnet, in association with the lowest dosage of the drug administered systematically (90 mg/kg/day), was effective in healing the retinal lesions. The main systemic side effects, such as renal impairment and electrolytic disturbances, were observed only during the induction treatment, and only in one case was it necessary to stop the therapy.

KW - AIDS

KW - CMV retinitis

KW - Foscarnet

KW - Intravitreal therapy

UR - http://www.scopus.com/inward/record.url?scp=0030036137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030036137&partnerID=8YFLogxK

M3 - Article

C2 - 8823593

AN - SCOPUS:0030036137

VL - 6

SP - 179

EP - 182

JO - European Journal of Ophthalmology

JF - European Journal of Ophthalmology

SN - 1120-6721

IS - 2

ER -